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Abstract
Background: Platelets are commonly transfused to critically ill patients. Reports suggest an association between
platelet transfusion and infection. However, there is no large study to have determined whether platelet transfusion
in critically ill patients is associated with hospital-acquired infection.
Methods: We conducted a multi-centre study using prospectively maintained databases of two large academic
intensive care units (ICUs) in Australia. Characteristics of patients who received platelets in ICUs between 2008 and
2014 were compared to those of patients who did not receive platelets. Association between platelet administration and
infection (bacteraemia and/or bacteriuria) was modelled using multiple logistic regression and Cox regression, with blood
components as time-varying covariates. A propensity covariate adjustment was also performed to verify results.
Results: Of the 18,965 patients included, 2250 (11.9%) received platelets in ICU with a median number of 1 platelet unit
(IQR 1–3) administered. Patients who received platelets were more severely ill at ICU admission (mean Acute Physiology
and Chronic Health Evaluation III score 65 (SD 29) vs 52 (SD 25), p < 0.01) and had more comorbidities (31% vs 19%,
p < 0.01) than patients without platelet transfusion. Invasive mechanical ventilation (87% vs 57%, p < 0.01) and
renal replacement therapy (20% vs 4%, p < 0.01) were more frequently administered in patients receiving platelets than in
patients without platelets. On univariate analysis, platelet transfusion was associated with hospital-acquired infection in
the ICU (7.7% vs 1.4%, p < 0.01). After adjusting for confounders, including other blood components administered, patient
severity, centre, year, and diagnosis category, platelet transfusions were independently associated with infection (adjusted
OR 2.56 95% CI 1.98–3.31, p < 0.001). This association was also found in survival analysis with blood components as time-
varying covariates (adjusted HR 1.85, 95% CI 1.41–2.41, p < 0.001) and when only bacteraemia was considered (adjusted
OR 3.30, 95% CI 2.30–4.74, p <0.001). Platelet transfusions remained associated with infection after propensity
covariate adjustment.
Conclusions: After adjustment for confounders, including patient severity and other blood components, platelet
transfusion was independently associated with ICU-acquired infection. Further research aiming to better understand this
association and to prevent this complication is warranted.
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Background
Platelet (PLT) transfusion is used therapeutically in patients
who are bleeding [1], and is also recommended by guide-
lines [2] to reduce the risk of bleeding in patients with
thrombocytopenia (prophylactic transfusion). However, the
benefit of prophylactic PLT administration in non-bleeding
critically ill patients with thrombocytopenia has been ques-
tioned [3, 4]. This is important, as there is some evidence
suggesting that PLT administration is associated with
adverse effects including infection and sepsis [5, 6]. The
association between blood component administration and
hospital-acquired infection has been reported mainly for
red blood cells (RBC) [7–9]. Nonetheless, this association is
probably not restricted to RBC, as fresh frozen plasma
(FFP) and PLT transfusion can also cause post transfusion
immunomodulation [10].
Platelets play a key role in the inflammatory and im-
mune response, [11] and some authors have hypothesised
that PLT transfusion may lead to immunomodulation
[10, 12]. Nonetheless, there has been no large study
of PLT transfusion in ICU patients to investigate
whether PLT administration is associated with an in-
creased risk of developing hospital-acquired infection.
Patients admitted to an ICU are likely to be particu-
larly prone to transfusion-mediated immunomodula-
tion [13]. Therefore, we aimed to describe PLT
transfusion in a large cohort of critically ill patients
and to determine whether PLT transfusion is associ-
ated with hospital-acquired infection.
Methods
Patients and study design
This is a retrospective study conducted in the mixed
medical-surgical ICUs of two teaching hospitals in
Melbourne (Australia). All patients admitted to one of
these ICUs between July 2008 and September 2013 were
included in the study. The Alfred Hospital (affiliated to
Monash University), with a 45-bed ICU capacity, is a
tertiary hospital and state-wide referral centre for
trauma and heart and lung transplantation; the Austin
Hospital (affiliated to the University of Melbourne), with
a 20-bed ICU capacity, is a tertiary hospital and referral
centre for liver transplantation for the states of Victoria,
Tasmania and South Australia. The Research Ethics
Committees of both institutions approved the study
(LNR13/Austin/233 and Alfred 58/11).
Clinical data
Clinical data were those prospectively extracted from
local ICU databases used to collect and submit data to
the Australian New Zealand Intensive Care Society
(ANZICS) Adult Patient Database (APD). Data were
collected on gender, date of birth, comorbidities, ICU
and hospital admission and discharge dates, Acute
Physiology And Chronic Health Evaluation (APACHE
III) score at admission, ICU admission categories, re-
quirement for and dates of initiation and cessation of
mechanical ventilation (MV) or renal replacement
therapy (RRT), and patient vital status at ICU and
hospital discharge.
Transfusion data
Data on all blood components issued and transfused to
patients were retrieved from the blood bank laboratory
information systems of each hospital. For each PLT unit
administered, we recorded the date of transfusion, the
type of product (apheresis or pooled), the volume, and
the ABO and Rhesus D blood group. Administration of
RBC, FFP and cryoprecipitate (CRYO) were also
collected. Universal pre-storage leukodepletion was in-
troduced in Australia prior to the study period, and
therefore all blood products were pre-storage leukode-
pleted. Systematic screening of PLT for bacterial con-
tamination was implemented at the same time by the
Australian Red Cross Blood Service. PLT transfusion
practices in critically ill patients were according to clin-
ician discretion.
The national guidelines in place at the time of the
study were the Australian Society of Blood Transfusion
(ASBT) guidelines, which recommended prophylactic
PLT transfusion at a threshold of 10 to 20 × 109/L in
bone marrow failure and a threshold of 50 × 109/L prior
to surgery or invasive procedures, [14] and therapeutic
PLT transfusion in bleeding patients in whom
thrombocytopenia was considered a major contributor
factor, when the platelet count was less than 50 × 109/L
in the context of massive haemorrhage, or less than
100 × 109/L in the presence of diffuse microvascular
bleeding [14]. An observational study conducted in
Australia and New Zealand confirmed the compliance
with these guidelines in ICU patients during the same
study period with only 5% of PLT transfusions that were
inappropriate [15]. The updated guidelines published
towards the end of the study period specifically for
critical care included similar proposed thresholds for
prophylactic PLT transfusion in the absence of bleed-
ing (<20 × 109/L) and prior to invasive procedures
(<50 × 109/L) [16].
Microbiological data
Microbiological data were retrieved from the microbiol-
ogy laboratory records (KESTRAL system, www.kestral.-
com.au, Melbourne, Victoria, Australia) at the Austin
hospital, and from a prospectively maintained database
by the infectious disease department at the Alfred hos-
pital. Microbiological data included positive blood cul-
ture and positive urine culture (defined by the presence
of no more than two bacterial or Candida pathogens,
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and at 105 colony forming units (cfu)/mL or higher
[17]). Sample date and pathogens isolated were recorded.
When a pathogen known to be a frequent contaminant
of microbiological cultures (i.e. coagulase-negative
staphylococcus) was isolated, only cases with two or
more positive blood cultures with the same pathogen
were considered as bloodstream infection.
Statistical analysis
Descriptive statistics are reported as mean (standard de-
viation) or median (interquartile range) according to
data distribution. Hypothesis testing was performed
using the chi-square test for categorical variables, Stu-
dent t test for normally distributed data and Wilcoxon
rank-sum test for non-normally distributed data. The
relationship between PLT transfusion and ICU-acquired
infection was determined by logistic regression with
results reported using odds ratios (ORs) (95% confidence
interval (CI)). Model discrimination and calibration were
determined using the area under the receiver operating
characteristic (ROC) curve and the Hosmer-Lemeshow
statistic.
Infection was defined as either bacteraemia or bacteri-
uria occurring in the ICU after 48 hours of ICU stay.
Multivariate analysis was performed adjusting for gen-
der, APACHE III score, site, diagnosis category, year,
whether the patient received invasive MV or RRT, and
whether another type of transfusion (RBC, CRYO, or
FFP) had been given prior to the first dose of PLT.
Additional sensitivity analysis was performed, adjusting
for each patient’s propensity to receive a PLT transfu-
sion; the propensity variable was calculated by using the
predicted values of a multiple logistic regression model
of platelet transfusion from pre-admission variables in-
cluding comorbidity variables and the same variables as
the multivariate analysis. Cox proportional hazards re-
gression analysis was then performed, with the outcome
of time of first infection, and including transfusion
Table 1 Characteristics of patients with and without platelet (PLT) transfusion in the ICU
Variables All patients N = 18,965 Patients with PLT
transfusion N = 2250
Patients without PLT
transfusion N = 16,715
P value
Age, years, mean (SD) 60 (18) 59 (17) 60 (17) 0.04
Gender, male, n (%) 12 086 (63.7%) 1 511 (67.2%) 10 575 (63.3%) <0.01
APACHE III score, mean (SD) 54 (26) 65 (29) 52 (25) <0.01
Comorbidities
Any known comorbidity 3 838 (20%) 702 (31%) 3 136 (19%) <0.01
Cancera 857 (4.5%) 192 (8.5%) 665 (4.0%) <0.01
Hepatic diseaseb 674 (3.6%) 216 (9.6%) 458 (2.7%) <0.01
Immunocompromisedc 1 180 (6.2%) 311 (13.8%) 869 (5.2%) <0.01
IDDM 511 (2.7%) 60 (2.7%) 451 (2.7%) 0.93
Chronic respiratory disease 840 (4.4%) 92 (4.1%) 748 (4.5%) 0.40
CVD 754 (4%) 137 (6.1%) 617 (3.7%) <0.01
Chronic renal failure 422 (2%) 59 (2.6%) 363 (2.2%) 0.17
Admission diagnosis
Cardiovascular 5 161 (27%) 701 (31%) 4 460 (27%) <0.01
Gastrointestinal 3 595 (19%) 581 (26%) 3 014 (18%) <0.01
Haematological 152 (0.8%) 96 (4.3%) 56 (0.3%) <0.01
Neurological 1 586 (8.4%) 108 (4.8%) 1 478 (8.8%) <0.01
Renal/genitourinary 1 017 (5.4%) 108 (4.8%) 909 (5.4%) 0.2
Respiratory 1 467 (7.7%) 127 (5.6%) 1 340 (8%) <0.01
Sepsis 503 (2.7%) 73 (3.2%) 430 (2.6%) 0.06
Otherd 2 815 (14.8%) 82 (3.6%) 2 733 (16.4%) <0.01
Trauma 2 669 (14.1%) 374 (16.6%) 2 295 (13.7%) <0.01
Requirement for MV 11 531 (61%) 1 952 (87%) 9 579 (57%) <0.01
Requirement for RRT 1 135 (6%) 449 (20%) 686 (4%) <0.01
aCancer group includes myeloma, lymphoma, leukaemia and metastases. bHepatic disease group includes liver cirrhosis, chronic liver disease and hepatic failure.
cImmunocompromised includes those listed as immunosuppressed or with immune disease. dOther includes undefined, metabolic, muscle and skin, gynaecologic
diseases. PLT platelets, ICU intensive care unit, MV mechanical ventilation, RRT replacement renal therapy, APACHE Acute Physiology And Chronic Health Evaluation,
IDDM insulin-dependent diabetes mellitus, CVD chronic vascular diseases, SD standard deviations. P values comparing PLT transfusion group to the no-PLT transfusion group
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variables as time-varying covariates, and gender, APA-
CHE III score, site, diagnosis category, year, and require-
ment for RRT and MV. Finally, three additional models
were then also performed, considering only bacteraemia
or bacteriuria as the infectious outcome and considering
the number of platelet units transfused as a continuous
variable. Propensity assumptions were determined using
Schoenfeld residuals. To increase the robustness of our
findings, a two-sided p value of 0.01 was considered to
indicate significance. Statistical analysis was performed
using STATA version 12.1 (StataCorp, TX, USA).
Results
Patient characteristics
A total of 19,101 patients had at least one admission to
of the either ICUs over the five and half year study
period. Of these, 136 (0.7%) were excluded because of
missing data, leaving 18,965 included in the present
study. Of the 18,965 patients, 2250 (11.9%) received PLT
in the ICU.
Patients’ characteristics and comparisons between pa-
tients who received PLT in the ICU and those who did
not are displayed in Table 1. Patients who received PLT
were younger (59 ± 17 vs 60 ± 17, p = 0.036) and more
often male (67.2% vs 63.3%, p < 0.01) than those who did
not receive PLT. They had greater illness severity at ICU
admission, with an APACHE III score of 65 ± 29 vs 52 ±
25 (p < 0.01) and they more often had comorbidities
(31% vs 19%, p < 0.01). Patients who received PLT in the
ICU were more often admitted with cardiovascular disease,
gastrointestinal (GI) disease, trauma, or haematological dis-
ease than those who did not receive PLT. The majority of
patients receiving PLT required invasive MV (87% vs 57%,
p < 0.01) and one fifth had RRT while in the ICU (20% vs
4%, p < 0.01).
Transfusion characteristics
PLT units (n = 6012) were transfused over the study
period, with a median of 1 PLT unit (IQR 1–3) per pa-
tient. Patients with haematology admission diagnosis re-
ceived more PLTs than the other critically ill patients.
The ABO group of the PLT unit transfused was known
in 2685 units and was mostly groups O (56%) and A
(40%). PLT transfusions were Rhesus-D-positive in 71%
of patients. Patients transfused with PLT were also trans-
fused with RBC, FFP and CRYO in 79%, 62% and 33% of
cases, respectively. These figures were significantly
higher (p < 0.01) than in patients without PLT transfu-
sion (RBC 21%, FFP 6%, cryoprecipitate 0.8%). The first
PLT transfusion occurred in the first 24 hours after ICU
admission in 82.6% of patients.
PLT transfusion and infections
Overall, 411 patients (2.2%) experienced an ICU-
acquired infection in ICU that was either bacteraemia or
bacteriuria (Table 2). A much higher proportion of
Table 2 Platelet exposure and outcomes
Variables All patients N = 18,965 Patients with PLT
transfusion N = 2250
Patients without PLT
transfusion N = 16,715
P value*
Infections, n (%)















Time to infection, days median (IQR)















PLT platelets, IQR interquartile range. *P values comparing PLT transfusion group to the no-PLT transfusion group
Table 3 Microbiological features of positive urine cultures occurring in patients with and without PLT transfusion in the intensive care unit
Pathogens Patients with positive
UC N = 292
Patients with positive UC
and with PLT transfusion
N = 99




Enterobactericeae Enterococcus 17 (5.8%) 43 (43.4%) 108 (56%) 0.04
Staphylococcus sp. 38 (19.5%) 2 (2%) 15 (7.8%) 0.04
Candida sp. 7 (2.4%) 3 (3%) 4 (2.1%) 0.44
Non-fermentive GNB 90 (30.8%) 44 (44.4%) 46 (23.8%) < 0.01
Other 30 (10.3%) 9 (9.1%) 21 (10.9%) 0.63
2 (0.7%) 1 (1%) 1 (0.5%) 0.56
UC with >1 microorganism 25 (8.6%) 5 (5.1%) 20 (10.4%) 0.12
PLT platelets, GNB Gram-negative Bacilli; UC urine culture. P values comparing PLT transfusion group to the no-PLT transfusion group
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patients who had received platelets developed infection
(7.7%) compared to those who had not (1.4%) (p < 0.01).
PLT transfusion was associated with occurrence of both
bacteraemia and bacteriuria (Table 2). Patterns of patho-
gens isolated in blood culture and urine culture are dis-
played in Tables 3 and 4.
After adjusting for confounders (gender, APACHE III
score, site, diagnosis category, year, whether another type
of transfusion had been given prior to the PLT transfu-
sion, MV and/or RRT requirement), PLT transfusion was
associated with an increased risk of infection (adjusted
odds ratio (OR) 2.56, 95% confidence interval (CI)
1.98–3.31, p < 0.01). The other independent risk factors
for infection were female gender, patient severity at ad-
mission, requirement for invasive MV, requirement for
RRT, admission diagnosis, administration of RBC prior
to PLT transfusion and year (Table 5). As there were no
significant interactions between PLT transfusion and
other variables in the model, there was no evidence to
suggest that the relationship between PLT transfusion
and infection differed according to any of the covariates
considered, including diagnosis category. When adjust-
ing for the propensity to receive platelet transfusion,
PLT transfusion remained associated with an increased
risk of infection (Appendix).
When considering blood product transfusion (PLT,
RBC, FFP or CRYO) as time-varying covariates, PLT
administration remained associated with infection
(adjusted HR 1.85, 95% CI 1.41–2.41, p < 0.01) (Table 6).
When considering bacteraemia and bacteriuria separ-
ately, PLT transfusion was still associated with each in-
fection outcome (adjusted OR for bacteraemia 3.30, 95%
CI 2.30 − 4.74, p <0.01 and adjusted OR for bacteriuria
2.01, 95% CI 1.44–2.83, p <0.01). There was a dose effect
in the association between PLT transfusion and infection
(adjusted OR for one PLT unit 1.62, 95% CI 1.11–2.35,
p = 0.01; adjusted OR for two PLT units 3.48, 95% CI
2.60–4.68, p < 0.01). Figure 1 shows the survival time
Table 4 Microbiological features of positive blood cultures in patients with and without PLT transfusion
Pathogens Patients with positive
blood culture N = 195
Patients with positive
blood culture who had
PLT transfusion N = 108
Patients with positive
blood culture without
PLT transfusion N = 87
P value
Enterobactericeae 54 (27.7%) 28 (26%) 26 (29%) 0.54
Enterococcus 38 (19.5%) 27 (25%) 11 (13%) 0.03
Staphylococcus aureus 20 (10.3%) 9 (8.3%) 11 (12.6%) <0.01
CNS 39 (20%) 21 (19.4%) 18 (20.7%) 0.83
Candida 36 (18.5%) 26 (24.1%) 10 (11.5%) 0.02
Non-fermentive GNB 16 (8.2%) 7 (6.5%) 9 (10.3%) 0.33
Other 2 (1%) 1 (0.9%) 1 (1.2%) 0.88
BC with >1 microorganism 14 (7.2%) 9 (8.3%) 5 (5.8%) 0.49
PLT Platelets, CNS coagulase negative Staphylococcus, GNB Gram-negative Bacilli, BC blood culture. P values comparing PLT transfusion group to the no-PLT
transfusion group







PLT 2.56 1.98-3.31 <0.01
Gender, male 0.40 0.33-0.50 <0.01
APACHE III score 1.01 1.00-1.01 <0.01
RBC transfusionb 1.50 1.19-1.90 <0.01
FFP transfusionb 0.92 0.68-1.24 0.57




RRT 4.75 3.56-6.32 <0.01
aOther confounders include centre, year and admission diagnosis. bOnly blood
products transfused prior to platelets (PLT) transfusion are considered in the
analysis. RBC red blood cells, FFP fresh frozen plasma, RRT renal replacement
therapy, APACHE III Acute Physiology And Chronic Health Evaluation III.
*Hosmer-Lemeshow p value >0.54, area under the receiver operating characteristic
curve 0.83






PLT transfusion 1.85 1.41-2.41 <0.01
Gender 0.43 0.35-0.52 <0.01
APACHE III score 1.00 1.00-1.01 0.20
RBCb 1.02 0.79-1.33 0.86
FFPb 0.87 0.66-1.14 0.32




RRT 1.33 1.03-1.71 0.03
aOther confounders include centre, year and admission diagnosis. bOnly blood
products transfused prior to infection are considered in the analysis. RBC red
blood cells, FFP fresh frozen plasma, RRT renal replacement therapy, PLT platelets,
APACHE Acute Physiology And Chronic Health Evaluation
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analysis for infection in patients with and without PLT
and Fig. 2 shows the survival time analysis for bacter-
aemia in patients with and without PLT.
Discussion
In this large observational study, PLT transfusion was
associated with ICU-acquired infection. This association
remained after adjustment for important confounders,
including administration of other blood products prior
to PLT administration and when considering all blood
components as time varying covariates. PLT transfusion
was still an independent risk factor for infection when
considering separately bacteraemia and bacteriuria as an
outcome.
Comparison with the available literature
It has been suggested that there is an association
between infections and PLT administration in trauma
and post-cardiac-surgery settings [5, 6, 18]. In a post hoc
analysis of data from six randomised trials, Spiess et al.
found that PLT transfusion was associated with an in-
creased risk of critical adverse events including infection
[5]. Nonetheless, the study conducted by Spiess et al.
was performed before the widespread use of
leukoreduction of blood components and its statistical
analysis did not adjust for all other blood components
administered.
More recently, Bilgin et al. reported on 1085 cardiac
surgery patients in whom the risk of death due to post-
Fig. 1 Kaplan-Meier estimates of infection in all patients over 40 days after ICU admission (p < 0.01 by the log-rank test)
Fig. 2 Kaplan-Meier estimates of bloodstream infections in all patients over 40 days after ICU admission (p < 0.01 by the log-rank test) )
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surgical infection was independently associated with
PLT transfusion [6]. However, the criteria to define in-
fection were not objective, with infection diagnosis based
on the “physician’s opinion”. In both studies, microbiol-
ogy data were not provided. In contrast, there was no
association between PLT transfusion and infection or
morbidity in other large cohorts of patients who had
undergone cardiac surgery [19–21]. Despite these
conflicting results, the plausibility of this association
is supported by reports showing the independent role
of PLT in transfusion-related immunomodulation in
animals [10].
Strengths and limitations
To our knowledge, this is the largest available study investi-
gating the association between PLT transfusion and
hospital-acquired infections in critically ill patients. Its het-
erogeneous population and its multi-centre design support
the generalizability of our findings. The consistent results
with different modelling approaches and the consideration
of transfusion of blood components as time-varying to
overcome survival bias is another strength that has not
been used commonly in similar studies on this topic. The
use of prospectively maintained databases of infectious
outcomes and microbiology criteria to define infection
also reduced bias, which may be introduced if relying
on subjective definitions of infection by clinicians.
Nonetheless, our study has some limitations. Its retro-
spective design did not allow adjustment for relevant but
missing data. Although we did perform propensity
covariate adjustment to account for the probability of re-
ceiving a PLT transfusion, estimation of the propensity
score could only be based on the available data. Infec-
tions that could not be reliably identified in our data
could not be included in the analysis, such as ventilator-
associated pneumonia or abdominal infections. Bacter-
aemia sources were not recorded, making it impossible
to classify bacteraemia according to the infection source.
There was no information on whether the patient was
on antibiotics at the time the microbiology samples were
obtained. Such information would have been useful to
better understand the relatively low rate of infection in
our population. Data were not available on blood com-
ponents given prior to ICU admission, and infections
occurring after ICU discharge. Finally, although we
adjusted for important factors known to influence the
risk of infection, we cannot exclude the possibility
that the observed associations were confounded by
unmeasured factors.
Implications of study findings
Our results suggest an association between PLT transfu-
sion and adverse clinical outcomes, and emphasise the
importance of avoiding unnecessary transfusions. Avoiding
unnecessary transfusion should be a priority and may
decrease hospital-acquired infection [3].
Conclusion
In conclusion, we found an independent association be-
tween PLT transfusion and the risk of hospital-acquired
infections in critically ill patients. This association
should be taken into account when transfusing PLT in
critically ill patients. Further research to understand this
association and to better determine the benefit of PLT in




APACHE: Acute Physiology And Chronic Health Evaluation; CI: Confidence
interval; Cryo: Cryoprecipitate; FFP: Fresh frozen plasma; HR: Hazard ratio;
ICU: Intensive care unit; IQR: Interquartile range; MV: Mechanical ventilation;
OR: Odds ratio; PLT: Platelets; RBC: Red blood cells; RRT: Renal replacement therapy
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PLT 2.45 1.89-3.18 <0.01
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RRT 3.90 2.79-5.46 <0.01
Propensity covariatec 3.46 1.15-10.38 0.03
aOther confounders include centre, year and admission diagnosis. bOnly blood
products transfused prior to platelets (PLT) transfusion are considered in the
analysis. cPropensity covariate predicted by gender, site, diagnosis, immune
disease, immunosuppressed, chronic liver disease, year, red blood cells (RBC)
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